Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma

ConclusionsAltogether, these results suggest that IL-1 α in combination with cetuximab can induce a T cell-dependent anti-tumor immune response and may represent a novel immunotherapeutic strategy for EGFR-positive HNSCCs.

Source: Journal for Immunotherapy of Cancer - March 18, 2019 Category: Cancer & Oncology Source Type: research